International Journal of Biomedical Science and Research
Innovative Targets for Glioblastoma Treatment: Exploring Epitope-Specific and Metabolic Pathways Enhanced by AI In-sights
Abstract
Richard Murdoch Montgomery
Glioblastomas (GBMs) are aggressive brain tumours characterised by genetic heterogeneity, therapeutic resistance, and an immunosuppressive microenvironment. This article investigates promising therapeutic targets, focusing on epitope- specific approaches and metabolic pathways, complemented by artificial intelligence (AI) to enhance drug discovery and treatment efficacy. Epitope-specific therapies include targeting EGFRvIII, mutant IDH1/2, and immune checkpoints like PD-L1 and CTLA-4, alongside novel immunotherapy for H3K27M mutations. Metabolic pathways such as glutamine and lipid metabolism, glycolysis, and the IDO pathway offer additional opportunities for intervention. AI-driven tools, including neoantigen prediction, metabolic modelling, epitope selection, and drug repurposing, are transforming glioblastoma research by identifying actionable targets and accelerating therapeutic development. These advancements hold the potential to significantly improve glioblastoma outcomes.